Exactly. great Q by SOT on CPP destiny, and TB for summing it up; we’re about to cross the rubicon
not being a big deal = delivery challenge solved
Goal = skip (d) (t) then exit left gracefully via: 1) cellular degradation -> cell exit (pray for no off targets elsewhere) 2) forming part of the intracellular structure
From the screenshot, you can still see excellent skipping at t=28 at d=1.6 ug/eye which is heartening!
Preclinical work so far indicates a graceful exit; from OCT to Mouse/NHP tox workups, biomarkers etc. let’s pray FDA likes our efficacy vs safety profile
An FDA tick, opens the door to us potentially scaling up our no big deal platform across ocular, CNS, Kidney and other cell membrane targets
PYC Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)